NASDAQ
3.65USD
0.00 (0.00%)
We have scored 6 news catalysts on Revance Therapeutics, Inc. (RVNC) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.15). Most of the impact sits in price momentum and institutional appeal.
Market cap
381M
P/E
—
EPS
—
Beta
0.95
52W range
2.3-7.56
Day range
3.65–3.65
Open
3.65
Prev close
3.65
Volume
0
Avg volume
3M
Dividend
0.00
IPO
2014-02-06
No scored news tagged RVNC or its network in the window yet.
Show more RVNC articles →Revance Therapeutics, Inc. is a biotechnology company specializing in the research, manufacturing, and marketing of neuromodulators for diverse aesthetic and therapeutic uses across both domestic and international markets. The company's leading product candidate, DaxibotulinumtoxinA for injection, has concluded Phase III clinical evaluations for treating glabellar (frown) lines and cervical dystonia. This same drug is currently in Phase II clinical trials for addressing upper facial lines, moderate to severe dynamic forehead lines, and moderate to severe lateral canthal lines, following the successful completion of its Phase II trials for adult upper limb spasticity and plantar fasciitis. Beyond this, Revance is conducting preclinical studies for DaxibotulinumtoxinA as a potential migraine treatment and is developing a topical version for various indications. The company is also developing OnabotulinumtoxinA, intended as a biosimilar to BOTOX. A collaborative and licensing partnership with Viatris Inc. facilitates the development, manufacturing, and commercialization of onabotulinumtoxinA. Initially established in 1999 as Essentia Biosystems, Inc., the company officially rebranded as Revance Therapeutics, Inc. in April 2005 and maintains its corporate headquarters in Nashville, Tennessee.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Revance Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for RVNC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
